Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, +45

The Lancet

Hematological MalignancyNeuro-oncologyTreatment StrategiesMedicineStandard Temozolomide Therapy +11

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O⁶-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Ulrich Herrlinger, Niklas Schäfer, Astrid Weyerbrock, +33

Journal of Clinical Oncology

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET

Sied Kebir, Rolf Fimmers, Norbert Galldiks, +11

Clinical Cancer Research

Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide

Moritz Stuplich, Dariusch R. Hadizadeh, K. Kuchelmeister, +10

Journal of Clinical Oncology

Neuro-oncologyMedicineBrain Tumor BiologyProlonged PseudoprogressionNeurology +5

Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

Johannes Weller, Theophilos Tzaridis, Frederic Mack, +22

The Lancet Oncology

Neuro-oncologyTreatment StrategiesNeurological AssessmentCognitive PerformanceHealth-related Quality +12

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma

Niklas Schäfer, Gerrit H. Gielen, Sied Kebir, +13

Journal of Cancer Research and Clinical Oncology

Neuro-oncologyGliomaMedicineHigh-grade GliomasCancer Treatment +4

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab

Christina Schaub, Julia Tichy, Niklas Schäfer, +14

Journal of Neuro-Oncology

Prognostic FactorsNeuro-oncologyMedicineImmune Checkpoint InhibitorHigh-grade Gliomas +5

ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, +31

Neuro-Oncology

Ceteg/noa-09 TrialNeuro-oncologyRadiation MedicineRadiation TherapyMedicine +13

Carmustine (BCNU) plus Teniposide (VM26) in Recurrent Malignant Glioma

Frederic Mack, Niklas Schäfer, Sied Kebir, +5

Oncology

FLAIR-Only Progression in Bevacizumab-Treated Relapsing Glioblastoma Does Not Predict Short Survival

Christina Schaub, Susanne Greschus, M. Seifert, +15

Oncology